Similar strategies could also be used to target immune-checkpoint blockade aptamers (CTLA4, PD1, TIM3, etc.)to the tumor in order to reduce undesirable immune reactions in other tissues as well. The gene discussed is HAVCR2; the disease is neoplasm.